

Gary W Falk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5814225/publications.pdf>

Version: 2024-02-01

249
papers

17,937
citations

19608

61
h-index

14156

128
g-index

275
all docs

275
docs citations

275
times ranked

7726
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1739-1747.	2.4	19
2	Age of diagnosis in familial Barrett's associated neoplasia. <i>Familial Cancer</i> , 2022, 21, 115-120.	0.9	3
3	Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 525-534.e10.	2.4	57
4	Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1488-1498.e11.	2.4	21
5	Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 535-545.e15.	2.4	28
6	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	1.5	40
7	Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 51-59.e7.	0.5	21
8	Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk. <i>Gastroenterology</i> , 2022, 162, 439-453.	0.6	22
9	Can FLIP guide therapy in idiopathic esophagogastric junction outflow obstruction?. <i>Ecological Management and Restoration</i> , 2022, 35, .	0.2	5
10	Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study. <i>Gastroenterology</i> , 2022, 162, 1635-1649.	0.6	21
11	Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort. <i>American Journal of Gastroenterology</i> , 2022, 117, 413-423.	0.2	17
12	Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1126-1137.e2.	0.5	18
13	Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2485-2494.e15.	2.4	16
14	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2474-2484.e3.	2.4	57
15	Mast cell-pain connection in eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1895-1899.	2.7	14
16	Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. <i>American Journal of Gastroenterology</i> , 2022, 117, 559-587.	0.2	159
17	Development and Validation of Web-Based Tool to Predict Lamina Propria Fibrosis in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 272-279.	0.2	10
18	Rio de Janeiro Global Consensus on Landmarks, Definitions, and Classifications in Barrett's Esophagus: World Endoscopy Organization Delphi Study. <i>Gastroenterology</i> , 2022, 163, 84-96.e2.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Guideline to Practice: Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. American Journal of Gastroenterology, 2022, 117, 1177-1180.	0.2	8
20	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Journal of Allergy and Clinical Immunology, 2022, 150, 33-47.	1.5	5
21	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Gastroenterology, 2022, 163, 59-76.	0.6	33
22	Type II achalasia is associated with a comparably favorable outcome following per oral endoscopic myotomy. Ecological Management and Restoration, 2021, 34, .	0.2	6
23	Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett's esophagus. Gastrointestinal Endoscopy, 2021, 93, 1250-1257.e3.	0.5	12
24	Best Practices in Surveillance for Barrett's Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 59-75.	0.6	9
25	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
26	Low-grade dysplasia in Barrett's esophagus: More than meets the eye?. Gastrointestinal Endoscopy, 2021, 94, 909-911.	0.5	2
27	Transition of Care from Pediatric to Adult Care in Eosinophilic Esophagitis. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 722-726.	0.9	0
28	Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women. Journal of Clinical Gastroenterology, 2021, 55, 321-326.	1.1	11
29	Eosinophilic Esophagitis. JAMA - Journal of the American Medical Association, 2021, 326, 1310.	3.8	98
30	Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer. Scientific Reports, 2021, 11, 21304.	1.6	20
31	Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology, 2020, 158, 111-122.e10.	0.6	300
32	Low Yield of Cross-Sectional Imaging in Patients With Esophagogastric Junction Outflow Obstruction. Clinical Gastroenterology and Hepatology, 2020, 18, 1643-1644.	2.4	18
33	Persistent Basal Cell Hyperplasia Is Associated With Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1475-1482.e1.	2.4	42
34	Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study. Journal of Allergy and Clinical Immunology, 2020, 145, 255-269.	1.5	51
35	Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. Digestive Diseases and Sciences, 2020, 65, 2024-2035.	1.1	44
36	High Patient Disease Burden in a Cross-sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 524-529.	0.9	19

#	ARTICLE	IF	CITATIONS
37	Good news for the treatment of narrow-caliber esophagus in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 54-55.	0.5	0
38	Editorial: fluticasone propionate orally disintegrating tabletsâ€”interesting concept but is it going anywhere? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 990-991.	1.9	0
39	Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 750-759.	1.9	29
40	Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1629-1640.e4.	1.5	37
41	Modeling Epithelial Homeostasis and Reactive Epithelial Changes in Human and Murine Threeâ€”Dimensional Esophageal Organoids. <i>Current Protocols in Stem Cell Biology</i> , 2020, 52, e106.	3.0	19
42	Is the age of diagnosis of esophageal adenocarcinoma getting younger? Analysis at a tertiary care center. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.2	4
43	Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 31-39.e1.	0.5	33
44	Notch Signaling Mediates Differentiation in Barrettâ€™s Esophagus and Promotes Progression to Adenocarcinoma. <i>Gastroenterology</i> , 2020, 159, 575-590.	0.6	49
45	Generation and Characterization of Patientâ€”Derived Head and Neck, Oral, and Esophageal Cancer Organoids. <i>Current Protocols in Stem Cell Biology</i> , 2020, 53, e109.	3.0	45
46	Virtual Dysphagia Evaluation: Practical Guidelines for Dysphagia Management in the Context of the COVID-19 Pandemic. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 455-458.	1.1	28
47	An Analysis of the GIQuIC Nationwide Quality Registry Reveals Unnecessary Surveillance Endoscopies in Patients With Normal and Irregular Z-Lines. <i>American Journal of Gastroenterology</i> , 2020, 115, 1869-1878.	0.2	18
48	Novel Therapeutic Approaches to Eosinophilic Esophagitis. <i>Gastroenterology and Hepatology</i> , 2020, 16, 294-301.	0.2	0
49	Barrett's Esophagus. , 2019, , 279-290.e5.		1
50	Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrettâ€™s Esophagus to Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 864-868.	2.4	51
51	Overestimation of the diagnosis of eosinophilic colitis with reliance on billing codes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2434-2436.	2.0	7
52	Fibrostenotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF- α . <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 171-182.	1.5	41
53	Highâ€”resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2754-2766.	2.3	11
54	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1477-1488.e10.	2.4	16

#	ARTICLE	IF	CITATIONS
55	Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development. <i>EBioMedicine</i> , 2019, 49, 145-156.	2.7	8
56	Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium. <i>American Journal of Gastroenterology</i> , 2019, 114, 984-994.	0.2	92
57	Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration. <i>Gastroenterology</i> , 2019, 156, 838-842.	0.6	25
58	Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 257-263.e3.	0.5	20
59	2017 David Sun Lecture: Screening and Surveillance of Barrett's Esophagus: Where Are We Now and What Does the Future Hold?. <i>American Journal of Gastroenterology</i> , 2019, 114, 64-70.	0.2	4
60	Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue. <i>Oncotarget</i> , 2019, 10, 3592-3604.	0.8	7
61	Achalasia Patients Are at Nutritional Risk Regardless of Presenting Weight Category. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1243-1249.	1.1	20
62	Clinical Guidelines Update on the Diagnosis and Management of Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2122-2128.	1.1	42
63	The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 333-352.	2.3	72
64	Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. <i>Gastroenterology</i> , 2018, 154, 1282-1289.e2.	0.6	107
65	Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 477-488.	3.7	135
66	Cryotherapy and Radiofrequency Ablation for Eradication of Barrett's Esophagus with Dysplasia or Intramucosal Cancer. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1311-1319.	1.1	33
67	Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 495-503.e8.	2.4	90
68	Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 348-355.	0.5	87
69	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018, 155, 1022-1033.e10.	0.6	712
70	Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 130-138.e1.	1.5	45
71	Autophagy mediates epithelial cytoprotection in eosinophilic oesophagitis. <i>Gut</i> , 2017, 66, 1197-1207.	6.1	43
72	Columnar islands in Barrett's esophagus: Do they impact Prague C&M criteria and dysplasia grade?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1598-1603.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Management of Low-Grade Dysplasia in Barrett's Esophagus: Incremental Progress Continues. <i>Gastroenterology</i> , 2017, 152, 928-932.	0.6	6
74	Modeling Esophagitis Using Human Three-Dimensional Organotypic Culture System. <i>American Journal of Pathology</i> , 2017, 187, 1787-1799.	1.9	7
75	Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>American Journal of Gastroenterology</i> , 2017, 112, 1032-1048.	0.2	38
76	Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 1-17.e3.	0.5	50
77	Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial. <i>Gastroenterology</i> , 2017, 153, 681-688.e2.	0.6	99
78	Proton pump inhibitor-responsive oesophageal eosinophilia: too early to change clinical practice. <i>Gut</i> , 2017, 66, 979-980.	6.1	9
79	A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 240-248.	1.1	36
80	Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy. <i>Gastroenterology</i> , 2017, 152, 987-992.	0.6	54
81	Long-term outcomes for cryotherapy in Barrett's esophagus with high-grade dysplasia: just cracking the ice. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 633-635.	0.5	9
82	Presentation of the Julius M. Friedenwald Medal to Anil K. Rustgi. <i>Gastroenterology</i> , 2017, 152, 2063-2067.	0.6	2
83	Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2017, 152, 776-786.e5.	0.6	166
84	Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study. <i>PLoS ONE</i> , 2017, 12, e0184962.	1.1	6
85	Creating a multi-center rare disease consortium – the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Translational Science of Rare Diseases</i> , 2017, 2, 141-155.	1.6	30
86	Current Management of Low-Grade Dysplasia in Barrett Esophagus. <i>Gastroenterology and Hepatology</i> , 2017, 13, 221-225.	0.2	2
87	Eosinophilic Esophagitis-Associated Chemical and Mechanical Microenvironment Shapes Esophageal Fibroblast Behavior. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 63, 200-209.	0.9	29
88	Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. <i>Molecular Carcinogenesis</i> , 2016, 55, 1526-1541.	1.3	20
89	A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 958-968.	1.1	45
90	Four Approaches to Reinvigorate Learning for the 21st Century Gastroenterologist. <i>Gastroenterology</i> , 2016, 151, 218-221.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1842-1844.	2.4	19
92	Findings of Esophagography for 25 Patients After Peroral Endoscopic Myotomy for Achalasia. <i>American Journal of Roentgenology</i> , 2016, 207, 1185-1193.	1.0	16
93	Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 407-419.	0.6	4
94	Esophageal cancer: The latest on chemoprevention and state of the art therapies. <i>Pharmacological Research</i> , 2016, 113, 236-244.	3.1	33
95	ATG7 Gene Expression as a Novel Tissue Biomarker in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2016, 111, 151-153.	0.2	11
96	Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 727-735.	1.1	10
97	Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1011-1014.	1.5	34
98	ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2016, 111, 30-50.	0.2	1,275
99	Updated Guidelines for Diagnosing and Managing Barrett Esophagus. <i>Gastroenterology and Hepatology</i> , 2016, 12, 449-51.	0.2	3
100	Control of Acid and Duodenogastroesophageal Reflux (DGER) in Patients With Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2015, 110, 1143-1148.	0.2	5
101	Esophageal epithelial cells acquire functional characteristics of activated myofibroblasts after undergoing an epithelial to mesenchymal transition. <i>Experimental Cell Research</i> , 2015, 330, 102-110.	1.2	37
102	Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, xiii.	1.0	1
103	Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2015, 44, xiii.	1.0	1
104	Barrett's oesophagus: Frequency and prediction of dysplasia and cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 125-138.	1.0	11
105	Endoscopic submucosal dissection for Barrett-associated neoplasia: is it ready for the endoscopist's toolbox?. <i>Endoscopy</i> , 2015, 47, 97-98.	1.0	3
106	Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 412-419.	1.2	14
107	Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1158-1166.e4.	0.5	34
108	Associations of Serum Adiponectin and Leptin With Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2265-2272.	2.4	23

#	ARTICLE	IF	CITATIONS
109	Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 665-672.e4.	2.4	42
110	The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 81, 1087-1100.e1.	0.5	47
111	BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015, 110, 662-682.	0.2	116
112	Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 299-315.	1.0	20
113	An Unusual Cause of Abdominal Pain. <i>Gastroenterology</i> , 2015, 149, e1-e2.	0.6	2
114	Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, xiii.	1.0	0
115	Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study. <i>Endoscopy</i> , 2015, 47, 669-674.	1.0	22
116	Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. <i>Gastroenterology</i> , 2015, 149, 1599-1606.	0.6	81
117	Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. <i>Gastroenterology</i> , 2015, 149, 567-576.e3.	0.6	77
118	Barrett's oesophagus length is established at the time of initial endoscopy and does not change over time: results from a large multicentre cohort. <i>Gut</i> , 2015, 64, 1874-1880.	6.1	11
119	BMP-driven NRF2 activation in esophageal basal cell differentiation and eosinophilic esophagitis. <i>Journal of Clinical Investigation</i> , 2015, 125, 1557-1568.	3.9	90
120	Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia. <i>Oncotarget</i> , 2015, 6, 32980-33005.	0.8	10
121	Radiofrequency ablation for Barrett's esophagus. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 415-421.	1.0	3
122	Clinical Presentation of Eosinophilic Esophagitis in Adults. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 231-242.	1.0	16
123	Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, xiii.	1.0	2
124	Update on Ablation for Barrett's Esophagus. <i>Current Gastroenterology Reports</i> , 2014, 16, 368.	1.1	0
125	Management of Early-stage Esophageal Neoplasia (MESEN) Consensus. <i>World Journal of Surgery</i> , 2014, 38, 96-105.	0.8	1
126	Gastroesophageal Reflux Disease. <i>Gastroenterology Clinics of North America</i> , 2014, 43, xi-xii.	1.0	0

#	ARTICLE	IF	CITATIONS
127	Upper GI Bleeding. <i>Gastroenterology Clinics of North America</i> , 2014, 43, xiii.	1.0	0
128	Biologics of IBD. <i>Gastroenterology Clinics of North America</i> , 2014, 43, xiii.	1.0	0
129	Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems. <i>Experimental Biology and Medicine</i> , 2014, 239, 1108-1123.	1.1	15
130	T-Helper 2 Cytokines, Transforming Growth Factor β 1, and Eosinophil Products Induce Fibrogenesis and Alter Muscle Motility in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 146, 1266-1277.e9.	0.6	114
131	Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 71-77.	0.5	44
132	Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research. <i>Gastroenterology</i> , 2014, 146, 1586-1590.	0.6	5
133	In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). <i>Gastrointestinal Endoscopy</i> , 2014, 79, 211-221.	0.5	183
134	Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. <i>Nature Medicine</i> , 2013, 19, 1005-1013.	15.2	351
135	Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. <i>Gastrointestinal Endoscopy</i> , 2013, 77, 190-199.	0.5	58
136	Association Between Length of Barrett's Esophagus and Risk of High-grade Dysplasia or Adenocarcinoma in Patients Without Dysplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1430-1436.	2.4	117
137	Recurrence of Esophageal Intestinal Metaplasia After Endoscopic Mucosal Resection and Radiofrequency Ablation of Barrett's Esophagus: Results From a US Multicenter Consortium. <i>Gastroenterology</i> , 2013, 145, 79-86.e1.	0.6	222
138	Modeling inflammation and oxidative stress in gastrointestinal disease development using novel organotypic culture systems. <i>Stem Cell Research and Therapy</i> , 2013, 4, S5.	2.4	28
139	Su1461 The Impact of Wide-Area Endoluminal Resection on Endoscopic Therapy for Barrett's Dysplasia and Early Carcinoma. <i>Gastrointestinal Endoscopy</i> , 2013, 77, AB332.	0.5	1
140	Location, location, location: does early cancer in Barrett's esophagus have a preference?. <i>Gastrointestinal Endoscopy</i> , 2013, 78, 462-467.	0.5	40
141	Persistence of Nondysplastic Barrett's Esophagus Identifies Patients at Lower Risk for Esophageal Adenocarcinoma: Results From a Large Multicenter Cohort. <i>Gastroenterology</i> , 2013, 145, 548-553.e1.	0.6	81
142	Update on the use of radiofrequency ablation for treatment of barrett esophagus. <i>Gastroenterology and Hepatology</i> , 2013, 9, 447-9.	0.2	0
143	Variation in Age at Cancer Diagnosis in Familial versus Nonfamilial Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 376-383.	1.1	26
144	Association of insulin and insulin-like growth factors with Barrett's oesophagus. <i>Gut</i> , 2012, 61, 665-672.	6.1	71

#	ARTICLE	IF	CITATIONS
145	Subsquamous Intestinal Metaplasia: Implications for Endoscopic Management of Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 220-224.	2.4	14
146	Diseases of the Esophagus. , 2012, , 874-886.		0
147	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. <i>Gastroenterology</i> , 2012, 143, 336-346.	0.6	365
148	Development of Subsquamous High-Grade Dysplasia and Adenocarcinoma After Successful Radiofrequency Ablation of Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 564-566.e1.	0.6	128
149	A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 917-926.e1.	0.6	58
150	The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 2012, 76, 252-254.	0.5	140
151	Poor discriminatory function for endoscopic skills on a computer-based simulator. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 993-1002.	0.5	17
152	Diagnosis and Surveillance of Barrett's Esophagus. , 2012, , 321-339.		0
153	Barrett's Esophagus Surveillance: When, How Often, Does It Work?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 9-24.	0.6	5
154	Patients With Nondysplastic Barrett's Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 220-227.e1.	2.4	211
155	Risk Factors for Progression of Low-Grade Dysplasia in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2011, 141, 1179-1186.e1.	0.6	238
156	Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. <i>Gastroenterology</i> , 2011, 141, 460-468.	0.6	432
157	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 3-20.e6.	1.5	1,839
158	Probe-based confocal endomicroscopy in Barrett's esophagus: the real deal or another tease?. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 473-476.	0.5	4
159	Barrett's esophagus: surveillance and reversal. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 196-209.	1.8	4
160	Barrett's esophagus: prevalenceâ€“incidence and etiologyâ€“origins. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 1-17.	1.8	24
161	Barrett's esophagus: endoscopic diagnosis. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 53-75.	1.8	12
162	The Role of Allergy Evaluation in Adults With Eosinophilic Esophagitis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 22-27.	1.1	74

#	ARTICLE	IF	CITATIONS
163	Radiofrequency Ablation of Barrett's Esophagus: Let's Not Get Ahead of Ourselves. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1811-1814.	1.1	7
164	Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G571-G581.	1.6	99
165	A Segregation Analysis of Barrett's Esophagus and Associated Adenocarcinomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 666-674.	1.1	39
166	Cutting to the chase: circumferential endoscopic mucosal resection for Barrett's neoplasia. <i>Gut</i> , 2010, 59, 1163-1164.	6.1	2
167	Evidence for DNA Damage Checkpoint Activation in Barrett Esophagus. <i>Translational Oncology</i> , 2010, 3, 33-42.	1.7	6
168	M1104 Predicting High-Grade Dysplasia (HGD) and Esophageal Adenocarcinoma (EAC) in Patients With Non-Dysplastic Barrett's Esophagus (BE): Results From a Large, Multicenter Cohort Study. <i>Gastroenterology</i> , 2010, 138, S-333.	0.6	3
169	92 Durability of Epithelial Reversion After Radiofrequency Ablation: Follow-up of the AIM Dysplasia Trial. <i>Gastroenterology</i> , 2010, 138, S-16-S-17.	0.6	6
170	Inhibition of Transient Lower Esophageal Sphincter Relaxation in GERD: Will Lesogaberan Advance the Field?. <i>Gastroenterology</i> , 2010, 139, 377-379.	0.6	4
171	Management of Nondysplastic Barrett's Esophagus: Where Are We Now?. <i>American Journal of Gastroenterology</i> , 2009, 104, 805-808.	0.2	24
172	Assessment of Familiarity, Obesity and Other Risk Factors for Early Age of Cancer Diagnosis in Adenocarcinomas of the Esophagus and Gastroesophageal Junction. <i>American Journal of Gastroenterology</i> , 2009, 104, 1913-1921.	0.2	44
173	Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. <i>New England Journal of Medicine</i> , 2009, 360, 2277-2288.	13.9	1,348
174	An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 635-644.	0.5	156
175	887 Integrated Pathways of Fibrogenesis in Eosinophilic Esophagitis: Active Secretion of Th2 Cytokines and TGF- β 1, and Binding of Activated Eosinophils Promote Collagen I and Fibronectin Production By Human Esophageal Mesenchymal Cells. <i>Gastroenterology</i> , 2009, 136, A-137.	0.6	1
176	Radiofrequency Ablation of Barrett's Esophagus: Should Everybody Get it?. <i>Gastroenterology</i> , 2009, 136, 2399-2401.	0.6	7
177	Antireflux Therapy in Asthma: Is There Any Role?. <i>Gastroenterology</i> , 2009, 137, 1844-1846.	0.6	1
178	Autofluorescence Endoscopy. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2009, 19, 209-220.	0.6	40
179	The Seattle Protocol Does Not More Reliably Predict the Detection of Cancer at the Time of Esophagectomy Than a Less Intensive Surveillance Protocol. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 653-658.	2.4	94
180	Risk Factors for Esophageal Cancer Development. <i>Surgical Oncology Clinics of North America</i> , 2009, 18, 469-485.	0.6	92

#	ARTICLE	IF	CITATIONS
181	Role of barium esophagography in evaluating dysphagia. Cleveland Clinic Journal of Medicine, 2009, 76, 105-111.	0.6	17
182	Decision Making in Ablation: Disease, Patients, and Institutional Factors. , 2009, , 63-89.		0
183	In reply: Barium esophagography (February 2009). Cleveland Clinic Journal of Medicine, 2009, 76, 218.2-218.	0.6	0
184	213 A Randomized, Multicenter, Sham-Controlled Trial of Radiofrequency Ablation (RFA) for Subjects with Barrett's Esophagus (Be) Containing Dysplasia: Interim Results of the Aim Dysplasia Trial. Gastroenterology, 2008, 134, A-37.	0.6	25
185	Obesity and Gastroesophageal Reflux Disease: Another Piece of the Puzzle. Gastroenterology, 2008, 134, 1620-1622.	0.6	5
186	Refractory GERD: Further Insights Into the Cause of Symptoms. Gastroenterology, 2008, 135, 1414-1415.	0.6	4
187	Is Conventional Endoscopic Identification of Non-Erosive Reflux Disease Adequate?. Digestion, 2008, 78, 17-23.	1.2	11
188	Chemoprevention and Barrett's Esophagus: Decisions, Decisions. American Journal of Gastroenterology, 2008, 103, 2443-2445.	0.2	7
189	Eosinophilic esophagitis: An increasingly recognized cause of dysphagia, food impaction, and refractory heartburn. Cleveland Clinic Journal of Medicine, 2008, 75, 623-633.	0.6	22
190	Extent of Low-Grade Dysplasia in Barrett's Esophagus: Is It Useful for Risk Stratification?. American Journal of Gastroenterology, 2007, 102, 494-496.	0.2	20
191	Is FDG-PET indicated for superficial esophageal cancer?†. European Journal of Cardio-thoracic Surgery, 2007, 31, 791-796.	0.6	48
192	Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma. Translational Research, 2007, 150, 3-17.	2.2	14
193	Night Vision Goggles for Surveillance of Barrett's Esophagus: A Paradigm Shift is Coming!. Gastroenterology, 2007, 132, 1189-1191.	0.6	0
194	Cutting Endoscopically or Surgically for Superficial Esophageal Adenocarcinoma. Gastroenterology, 2007, 133, 360-362.	0.6	0
195	Laryngopharyngeal Reflux: Beauty is in The Eye of The Beholder. Gastroenterology, 2007, 133, 1379-1381.	0.6	4
196	How Exactly Do I Diagnose Intestinal Metaplasia in Barrett's Esophagus?. Gastroenterology, 2007, 133, 2060-2062.	0.6	2
197	Dysplasia and Cancer in a Large Multicenter Cohort of Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2006, 4, 566-572.	2.4	388
198	AGA Institute Medical Position Statement on the Use of Endoscopic Therapy for Gastroesophageal Reflux Disease. Gastroenterology, 2006, 131, 1313-1314.	0.6	18

#	ARTICLE	IF	CITATIONS
199	AGA Institute Technical Review on the Use of Endoscopic Therapy for Gastroesophageal Reflux Disease. <i>Gastroenterology</i> , 2006, 131, 1315-1336.	0.6	53
200	Eosinophilic esophagitis: New insights into an emerging disease. <i>Gastroenterology</i> , 2006, 131, 2018-2020.	0.6	6
201	Eosinophilic pancreatitis presenting as a pancreatic mass with obstructive jaundice. <i>Gastrointestinal Endoscopy</i> , 2006, 63, 525-527.	0.5	11
202	Turning an idea into a grant. <i>Gastrointestinal Endoscopy</i> , 2006, 64, S11-S13.	0.5	4
203	Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. <i>Cancer</i> , 2006, 107, 2160-2166.	2.0	87
204	Familiality in Barrett's Esophagus, Adenocarcinoma of the Esophagus, and Adenocarcinoma of the Gastroesophageal Junction. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1668-1673.	1.1	104
205	Barrett's Esophagus at a Tertiary Care Center: Association of Age on Incidence and Prevalence of Dysplasia and Adenocarcinoma. <i>American Journal of Gastroenterology</i> , 2006, 101, 2187-2193.	0.2	66
206	Gastric and Esophageal pH in Patients With Barrett's Esophagus Treated With Three Esomeprazole Dosages: A Randomized, Double-Blind, Crossover Trial. <i>American Journal of Gastroenterology</i> , 2006, 101, 1964-1971.	0.2	66
207	Barrett's Esophagus-Is It Bad for Your Health?. <i>American Journal of Gastroenterology</i> , 2005, 100, 2622-2623.	0.2	9
208	Barrett's Esophagus in Women: Demographic Features and Progression to High-Grade Dysplasia and Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1089-1094.	2.4	38
209	Esophageal manometry: Assessment of interpreter consistency. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 218-224.	2.4	50
210	Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. <i>Modern Pathology</i> , 2004, 17, 588-596.	2.9	53
211	<i>A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop 1</i> Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Janusz Ja. <i>Gastroenterology</i> , 2004, 127, 310-330.	0.6	579
212	Fluorescence in situ hybridization of cytologic specimens from Barrett's esophagus: a pilot feasibility study. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 280-284.	0.5	29
213	A coxib a day won't keep the doctor away. <i>Lancet</i> , The, 2004, 364, 639-640.	6.3	88
214	Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1537-1541.	1.1	99
215	Cytology in Barrett's esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2003, 13, 335-348.	0.6	19
216	Motility and Gi Function Studies Billing and Coding Guidelines: A Position Paper of The American Motility Society. <i>American Journal of Gastroenterology</i> , 2003, 98, 1228-1236.	0.2	12

#	ARTICLE	IF	CITATIONS
217	Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. American Journal of Gastroenterology, 2002, 97, 302-311.	0.2	83
218	Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. American Journal of Gastroenterology, 2002, 97, 1340-1345.	0.2	39
219	p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. American Journal of Gastroenterology, 2002, 97, 2508-2513.	0.2	124
220	Barrett's esophagus. Gastroenterology, 2002, 122, 1569-1591.	0.6	345
221	Progression of Barrett's esophagus to high grade dysplasia and cancer: Preliminary results of the BEST (Barrett's esophagus study) trial. Gastroenterology, 2001, 120, A16-A17.	0.6	11
222	Pathogenesis of Gastroesophageal Reflux and Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 226-234.	1.4	4
223	Superficial adenocarcinoma of the esophagus. Journal of Thoracic and Cardiovascular Surgery, 2001, 122, 1077-1090.	0.4	147
224	Pathogenesis of Gastroesophageal Reflux and Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 226-234.	1.4	38
225	Adenocarcinoma in Barrett's Esophagus: Signs, Symptoms and Endoscopic Appearance. , 2001, , 291-295.		0
226	Unresolved Issues in Barrett's Esophagus in the New Millennium. Digestive Diseases, 2000, 18, 27-42.	0.8	13
227	Caga-positive strains of Helicobacter pylori may protect against Barrett's esophagus. American Journal of Gastroenterology, 2000, 95, 2206-2211.	0.2	166
228	The gastric cardia: fact or fiction?. American Journal of Gastroenterology, 2000, 95, 921-924.	0.2	221
229	Endoscopic surveillance of Barrett's esophagus. Techniques in Gastrointestinal Endoscopy, 2000, 2, 186-193.	0.3	5
230	Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology, 2000, 119, 683-690.	0.6	114
231	Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointestinal Endoscopy, 2000, 52, 197-203.	0.5	138
232	The Incidence of Adenocarcinoma and Dysplasia in Barrett's Esophagus: Report on The Cleveland Clinic Barrett's Esophagus Registry. American Journal of Gastroenterology, 1999, 94, 2037-2042.	0.2	167
233	Role of Helicobacter pylori cagA+ strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. , 1999, 82, 520-524.		55
234	Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointestinal Endoscopy, 1999, 49, 170-176.	0.5	292

#	ARTICLE	IF	CITATIONS
235	Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. <i>Gastrointestinal Endoscopy</i> , 1999, 49, S29-S34.	0.5	31
236	The incidence of adenocarcinoma and dysplasia in Barrett's esophagus Report on the cleveland clinic barrett's esophagus registry. <i>American Journal of Gastroenterology</i> , 1999, 94, 2037-2042.	0.2	220
237	Gastroesophageal reflux disease. <i>Current Opinion in Gastroenterology</i> , 1999, 15, 333.	1.0	2
238	Why is esophageal adenocarcinoma increasing in incidence?. <i>Abdominal Imaging</i> , 1998, 23, 539-542.	2.0	4
239	The seroprevalence of cagA-positive <i>Helicobacter pylori</i> strains in the spectrum of gastroesophageal reflux disease. <i>Gastroenterology</i> , 1998, 115, 50-57.	0.6	369
240	Inflammation and intestinal metaplasia of the gastric cardia: The role of gastroesophageal reflux and <i>H. pylori</i> infection. <i>Gastroenterology</i> , 1998, 114, 633-639.	0.6	261
241	<i>Helicobacter pylori</i> and gastroesophageal reflux disease: the bug may not be all bad. <i>American Journal of Gastroenterology</i> , 1998, 93, 1800-1802.	0.2	98
242	Effect of pneumatic dilation on gastroesophageal reflux in achalasia. <i>Digestive Diseases and Sciences</i> , 1997, 42, 998-1002.	1.1	22
243	Editorial: Barrett's Esophagus and Adenocarcinoma. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 88-90.	1.1	12
244	Observer variation and reproducibility of endoscopic ultrasonography. <i>Gastrointestinal Endoscopy</i> , 1995, 41, 115-120.	0.5	69
245	Barrett's Esophagus. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1994, 4, 773-789.	0.6	18
246	p53 Immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1994, 108, 1132-1137.	0.4	47
247	Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia. <i>Gastrointestinal Endoscopy</i> , 1994, 40, 207-212.	0.5	99
248	Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1927-1927.	1.1	0
249	Effect of ozone and nitrogen dioxide on the agglutination of rat alveolar macrophages by concanavalin A. <i>Life Sciences</i> , 1977, 21, 1637-1644.	2.0	19